Quinn Ostrom

Overview:

I am a cancer epidemiologist with specialized training in genetic epidemiology. The overall goal of my research program is to identify genetic factors that increase the risk of developing a brain tumor as well as those that affect prognosis after diagnosis. My research focuses on: 1) using population-level cancer registry data for surveillance and risk factor discovery; 2) discovering sources of germline genetic risk for brain tumors and 3) understanding the relationship between immune traits and brain tumor risk and survival. I approach these questions through a research program of interrelated projects and application of novel analytic techniques.

Positions:

Assistant Professor in Neurosurgery

Neurosurgery, Neuro-Oncology
School of Medicine

Assistant Professor in Population Health Sciences

Population Health Sciences
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S. 2007

Michigan State University

M.A. 2010

Case Western Reserve University

M.P.H. 2012

Case Western Reserve University, School of Medicine

Ph.D. 2018

Case Western Reserve University, School of Medicine

Post Doctoral Associate

Baylor College of Medicine

Grants:

Central Brain Tumor Registry of the United States (CBTRUS) Statistical Analysis

Administered By
Neurosurgery, Neuro-Oncology
Awarded By
Central Brain Tumor Registry
Role
Principal Investigator
Start Date
End Date

Central Brain Tumor Registry of the United States (CBTRUS) Statistical Analysis

Administered By
Neurosurgery, Neuro-Oncology
Awarded By
Central Brain Tumor Registry
Role
Principal Investigator
Start Date
End Date

Publications:

Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma.

Authors
Ostrom, QT; Lu, D; Lu, R; Baker, MC
MLA Citation
Ostrom, Quinn T., et al. “Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma.Neuro Oncol, June 2022. Pubmed, doi:10.1093/neuonc/noac145.
URI
https://scholars.duke.edu/individual/pub1524918
PMID
35713330
Source
pubmed
Published In
Neuro Oncol
Published Date
DOI
10.1093/neuonc/noac145

ALIGNING THE CBTRUS HISTOLOGY GROUPS WITH 2016 WHO CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM

Authors
Kruchko, C; Patil, N; Cioffi, G; Brat, D; Bruner, J; McLendon, R; Tihan, T; Barnholtz-Sloan, J; Ostrom, Q
MLA Citation
Kruchko, Carol, et al. “ALIGNING THE CBTRUS HISTOLOGY GROUPS WITH 2016 WHO CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM.” Neuro Oncology, vol. 23, 2021, pp. 91–91.
URI
https://scholars.duke.edu/individual/pub1512483
Source
wos-lite
Published In
Neuro Oncology
Volume
23
Published Date
Start Page
91
End Page
91

Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians.

Background: The Central Brain Tumor Registry of the United States (CBTRUS) contains information on all primary brain and other central nervous system (CNS) tumors diagnosed in the United States (US). Here we summarize the 2021 CBTRUS annual statistical report for clinicians. Methods: Incidence survival data are obtained from the Centers for Disease Control's National Program of Cancer Registries (NPCR) and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Survival data are obtained from NPCR. Mortality data are obtained from the National Vital Statistics System. Incidence and mortality rates are age-adjusted using the 2000 US population and presented per 100,000 population. Results: An annual average of 86,355 cases of primary malignant and nonmalignant CNS tumors were diagnosed over the period 2014-2018, corresponding to an average annual age-adjusted incidence rate of 24.25. The most commonly occurring malignant tumor was glioblastoma (14.3%), and the most common predominately nonmalignant tumor was meningioma (39%). Over the 2014-2018 period, there were 16,606 annual average deaths due to malignant primary CNS tumors, corresponding to an average annual age-adjusted mortality rate of 4.43. In this report we detail key incidence, survival, and mortality statistics for major primary CNS tumor histologies, highlighting relevant differences by age, sex, and race. Conclusions: This summary describes the most up to date population-based incidence of primary malignant and nonmalignant brain and other CNS tumors in the US, and mortality and survival for primary malignant tumors and aims to serve as a useful resource for clinicians.
Authors
Low, JT; Ostrom, QT; Cioffi, G; Neff, C; Waite, KA; Kruchko, C; Barnholtz-Sloan, JS
MLA Citation
Low, Justin T., et al. “Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians.Neurooncol Pract, vol. 9, no. 3, May 2022, pp. 165–82. Pubmed, doi:10.1093/nop/npac015.
URI
https://scholars.duke.edu/individual/pub1510697
PMID
35601966
Source
pubmed
Published In
Neuro Oncology Practice
Volume
9
Published Date
Start Page
165
End Page
182
DOI
10.1093/nop/npac015

ASSOCIATIONS BETWEEN GERMLINE GENETIC VARIANTS AND OVERALL SURVIVAL IN PATIENTS WITH GLIOMA

Authors
Potnis, K; Ostrom, Q; Claus, E
MLA Citation
Potnis, Kunal, et al. “ASSOCIATIONS BETWEEN GERMLINE GENETIC VARIANTS AND OVERALL SURVIVAL IN PATIENTS WITH GLIOMA.” Neuro Oncology, vol. 23, 2021, pp. 86–86.
URI
https://scholars.duke.edu/individual/pub1512484
Source
wos-lite
Published In
Neuro Oncology
Volume
23
Published Date
Start Page
86
End Page
86

Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.

BACKGROUND: Selected molecular biomarkers were incorporated into U.S. cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables, and described the epidemiology of molecularly-defined brain tumor types. METHODS: Brain tumor patients with histopathologically-confirmed diagnosis in 2018 were identified within the Central Brain Tumor Registry of the United States and NCI's Surveillance, Epidemiology, and End Results Incidence databases. The brain molecular markers (BMM) site-specific data item was assessed for coding completeness and validity. 1p/19q status, MGMT promoter methylation, and WHO grade data items, and new ICD-O-3 codes were additionally evaluated. These data were used to profile the characteristics and age-adjusted incidence rates per 100,000 population of molecularly-defined brain tumors with 95% confidence intervals (95%CI). RESULTS: BMM completeness across the applicable tumor types was 75-92% and demonstrated favorable coding validity. IDH-wildtype glioblastomas' incidence rate was 1.74 (95%CI: 1.69-1.78), as compared to 0.14 for WHO grade 2 (95%CI: 0.12-0.15), 0.15 for grade 3 (95%CI: 0.14-0.16), and 0.07 for grade 4 (95%CI: 0.06-0.08) IDH-mutant astrocytomas. Irrespective of WHO grade, IDH mutation prevalence was highest in adolescent & young adult patients and IDH-mutant astrocytomas were more frequently MGMT promoter methylated. Among pediatric-type tumors, the incidence rate was 0.06 for H3K27M-mutant diffuse midline gliomas (95%CI: 0.05-0.07), 0.03 for SHH-activated/TP53-wildtype medulloblastomas (95%CI: 0.02-0.03), and <0.01 for both C19MC-altered ETMRs and RELA-fusion ependymomas. CONCLUSIONS: Our findings illustrate the success of developing a dedicated, integrated-diagnosis variable, which provides critical molecular information about brain tumors related to accurate diagnosis.
Authors
Iorgulescu, JB; Sun, C; Neff, C; Cioffi, G; Gutierrez, C; Kruchko, C; Ruhl, J; Waite, K; Negoita, S; Hofferkamp, J; Tihan, T; McLendon, R; Brat, DJ; Ostrom, QT; Barnholtz-Sloan, JS
MLA Citation
Iorgulescu, J. Bryan, et al. “Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.Neuro Oncol, Apr. 2022. Pubmed, doi:10.1093/neuonc/noac113.
URI
https://scholars.duke.edu/individual/pub1519468
PMID
35460555
Source
pubmed
Published In
Neuro Oncol
Published Date
DOI
10.1093/neuonc/noac113

Research Areas:

Brain--Tumors
Cancer Disparities
Cancer--Epidemiology
Genetic epidemiology
Genome-Wide Association Study
Glioma
Health Disparities
Molecular Epidemiology
Registries
SEER Program